The Unstable Angina Therapeutics Market Expected to Show Slow Growth until 2018

Monday 12 March 2012, Amsterdam

The report is an essential source of information and analysis on the global unstable angina therapeutics market. The report identifies the key trends shaping and driving the global unstable angina therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global unstable angina therapeutics sector.

The Unstable Angina Therapeutics Market Expected to Show Slow Growth until 2018

They estimated the global unstable angina therapeutics market to be worth $2,834.0m in 2010. It is expected to grow to $3,139.1m with a Compound Annual Growth Rate (CAGR) of 1.3% by 2018. This slow growth can be primarily attributed to the rise in the number of patients undergoing treatment for unstable angina and the expected approval of novel therapies such as rivaroxaban, varespladib and otamixaban, which are currently in the late stage of clinical development. However, if approved, these products are expected to be marketed at a premium price compared to other treatment options for unstable angina. The launch of products at premium prices is attributed to the novel mechanism of action of these products leading to a marked improvement in efficacy and safety over the currently marketed products. Therefore the market penetration of these products is expected to remain low in a generic dominated market, limiting the growth rate of the unstable angina therapeutics market. The forecast period will also witness patent expiries of major marketed products such as Lipitor (atorvastatin) in 2011, Aggrastat (tirofiban) in 2012, Angiomax/Angiox (bivalirudin) in 2015 in European countries, and Crestor (rosuvastatin) in 2016. The patent expiry of the major marketed products will attract generic versions of these drugs to the market. Therefore the unstable angina therapeutics market is expected to witness slow growth with numerous generics playing a major role in the forecast period; this is similar to the present market scenario.

Weak Current Competition in Unstable Angina Therapeutics Market

They assessed the current competitive landscape for unstable angina drugs and found that competition is weak. The available treatment options are moderately successful in meeting the market demand. The market has various treatment options available but none are able to adequately manage unstable angina. The products currently available in the market are associated with average efficacy and safety profiles.

The current treatment options offer poor quality of life due to their lack of efficacy in reducing cardiovascular events and mortality. As the products currently in the market do not serve the unmet need, the market continues to present opportunities for pipeline products with novel mechanisms of action and disease modifying characteristics. The unmet need in the unstable angina market is considered to be significant and can be fulfilled by technologically advanced products with improved safety and efficacy profiles.

Strong Pipeline with Novel Therapies Expected to Increase Competition in Unstable Angina Therapeutics Market

The research indicates that the unstable angina therapeutics market pipeline is strong. There are 12 molecules in the unstable angina pipeline across the various phases of clinical development. An analysis concludes that of the 12 molecules in the pipeline, eight molecules are first-in-class based on their unique or novel mechanism of action. In the late stage of clinical development (Phase III), three molecules are considered to be of commercial importance to the unstable angina therapeutics market and are expected to impact the market in the forecast period. Rivaroxaban, varespladib and otamixaban are currently in Phase III of clinical development and are expected to influence the market growth during the forecast period, following their approval and subsequent launch.

The first-in-class molecules in the unstable angina pipeline, such as otamixaban and rivaroxaban, are selective factor Xa inhibitors and are expected to offer a substantial reduction in major coronary complications in patients with unstable angina and Acute Coronary Syndrome (ACS). These products are more predictable than the currently-used antithrombotic agents in terms of thinning of the blood and limiting the need for frequent monitoring. These products are expected to meet the unmet needs in the unstable angina therapeutics market and provide patients and physicians with increased options; this will ultimately lead to increased competition in the market.